(3S)-4-[4-(2-acetyl-1-methyl-1H-imidazol-4-yl)phenyl]-3-[([3-chloro-4-[(1-methylethyl)oxy]phenyl}carbonyl)amino]butyl dimethyl phosphate → (3S)-4-[4-(2-acetyl-1-methyl-1H-imidazol-4-yl)phenyl]-3-[({3-chloro-4-[(1-methylethyl)oxy]phenyl}carbonyl)amino]butyl dihydrogen phosphate

HRID 222903

Reaktionsgleichung

Reaktionsgleichung von HRID 222903
[P:1]([O:39]C)([O:37]C)([O:3][CH2:4][CH2:5][C@@H:6]([NH:23][C:24]([C:26]1[CH:31]=[CH:30][C:29]([O:32][CH:33]([CH3:35])[CH3:34])=[C:28]([Cl:36])[CH:27]=1)=[O:25])[CH2:7][C:8]1[CH:13]=[CH:12][C:11]([C:14]2[N:15]=[C:16]([C:20](=[O:22])[CH3:21])[N:17]([CH3:19])[CH:18]=2)=[CH:10][CH:9]=1)=[O:2]>Br.CC(O)=O>[P:1]([OH:37])([OH:39])([O:3][CH2:4][CH2:5][C@@H:6]([NH:23][C:24]([C:26]1[CH:31]=[CH:30][C:29]([O:32][CH:33]([CH3:35])[CH3:34])=[C:28]([Cl:36])[CH:27]=1)=[O:25])[CH2:7][C:8]1[CH:13]=[CH:12][C:11]([C:14]2[N:15]=[C:16]([C:20](=[O:22])[CH3:21])[N:17]([CH3:19])[CH:18]=2)=[CH:10][CH:9]=1)=[O:2]

Komponenten

4

Edukt 1

HCID 57594157(3S)-4-[4-(2-acetyl-1-methyl-1H-imidazol-4-yl)phenyl]-3-[([3-chloro-4-[(1-methylethyl)oxy]phenyl}carbonyl)amino]butyl dimethyl phosphate

Produkt 1

HCID 16723062(3S)-4-[4-(2-acetyl-1-methyl-1H-imidazol-4-yl)phenyl]-3-[({3-chloro-4-[(1-methylethyl)oxy]phenyl}carbonyl)amino]butyl dihydrogen phosphateAusbeute 19 %

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 176Acetic AcidLösungsmittelHCID 260Hydrogen BromideLösungsmittel

Reaktionsbedingungen

Temperatur
60 °C

Versuchsvorschrift

A yellow solution of (3S)-4-[4-(2-acetyl-1-methyl-1H-imidazol-4-yl)phenyl]-3-[({3-chloro-4-[(1-methylethyl)oxy]phenyl}carbonyl)amino]butyl dimethyl phosphate (475 mg, 0.804 mmol) in 30% HBr in AcOH was placed in a pre-heated (60° C.) bath for 10 min, then immediately allowed to cool to rt. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in DMSO (6 mL), filtered and purified by Gilson reverse phase HPLC (MeCN/H2O with 0.1% TFA). The MeCN of the clean fractions was removed under reduced pressure and the remaining aqueous solution was frozen and lyophilized overnight to give 84 mg (19%) of the title compound as a yellow powder. LC/MS (ES) m/e 564.2 (M+H)+.

Aufarbeitung

  1. temperatureto cool to rt
  2. concentrationThe reaction mixture was concentrated under reduced pressure
  3. dissolutionthe residue was dissolved in DMSO (6 mL)
  4. filtrationfiltered
  5. custompurified by Gilson reverse phase HPLC (MeCN/H2O with 0.1% TFA)
  6. customThe MeCN of the clean fractions was removed under reduced pressure
  7. temperaturethe remaining aqueous solution was frozen

Quellen und Nachweise

ORD-Eintrag
ord-7ab5904eb11042dcbd6978f6a3eefed4
Quelldatensatz
uspto-grants-2012_06
Patentnummer
US08207340B2

Verknüpfte Notizen

Wird geladen…